In addition, percentage of Th22 cells (CD4+IFN‐γ−IL‐17−IL‐22+ cells) was notably increased in acute myocardial infarction (2.23 ± 1.58%) and unstable angina (2.09 ± 0.60%) patients compared with stable angina patients (0.93 ± 0.26%) or healthy controls (0.84 ± 0.18%).37 In contrast, the results of dilated cardiomyopathy (DCM) studies showed that Th22 cells may inhibit myocardial fibrosis, indicating that these cells may have a protective role in DCM.38 Thus, the role of Th22 cells in cardiovascular disease (CVD) needs to be further explored. This evidence concerns the gene CD4 and cardiovascular disorder.